Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics' Heart Health Test
... the results of clinical
studies that support the company's Heart Health Genetic Test to assess
cardiovascular risk. The article, titled, "IL1B Gene promoter
Pairs Predict Clinical Levels of Interleukin-1beta and C-reactive Protein,"
was published in the journal Human Genetics (123:387-398; May ...
Celldex Therapeutics Receives Fast-Track Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma
... of primary brain cancer and carries a very poor
prognosis with current therapy. CDX-110 is an immunotherapy that targets
the tumor-specific growth promoter
EGFRvIII that can be expressed by GBM.
In the ACTIVATE Phase 2a study, GBM patients treated with CDX-110
showed a median survival time of 30 ...
Celldex Therapeutics Announces Orphan Drug Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma Multiforme
... Multiforme (GBM). GBM is the most common
and aggressive form of brain cancer. CDX-110 is an immunotherapy that
targets the tumor-specific growth promoter
EGFRvIII. Celldex Therapeutics
announced a definitive merger agreement with AVANT Immunotherapeutics, Inc.
(Nasdaq: AVAN ) in October 2007.
In the ...
Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
... England, to humanize Lpathomab to create a lead antibody for pre-
clinical development. LPA is a bioactive lipid long recognized as a significant promoter
cancer-cell growth and metastasis in a broad range of tumor types, as well
as a significant contributor to neuropathic pain. "Humanizing our ...
Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial
Targeting System's Success in Mouse Model Reported in Cancer Cell
... mutant gene delivered via a
less-targeted viral promoter
driven expression system ... C-VISA-BikDD.
They used a gene-based targeting promoter
called CCKAR known to
be active in pancreatic ... after
A system using a viral promoter
such as CMV has the opposite
problem: strong ...
Merck at ASCO 2007: Encouraging Results in Progression-Free
Survival in Patients With Aggressive Brain Tumors (glioblastoma)
Using Cilengitide in Phase I/IIa Study
... of 8.1 months. In a
defined patient subgroup with the methylated MGMT gene promoter
the tumor tissue, 91% of patients had six months PFS and the median
has ... 54% 6 months PFS, median PFS of 6.9
months;(1) methylated MGMT gene promoter
subgroup: 69% PFS and 10.3
months median PFS].(2)
Lead investigator ...
Data Show SuperGen's Multi-Targeted Tyrosine Kinase Inhibitor
Suppresses Critical Double-Stranded DNA Repair Protein, Rad51
... inhibitors of DNA
methyltransferase (DNMT). DNMT1 is considered to be the DNA
methyltransferase enzyme mainly responsible for maintaining
methylation in various cancer types. Zebrafish
embryos are a viable model for cancer drug research because of
their close similarity to humans and ...
Telomerase Presentations at the AACR 2007 Annual Meeting
... of telomere loss prior to telomerase activation in various
tumor types, the role of telomere dysfunction in tumorigenesis, and
use of the telomerase promoter
to drive tumor cell death.
"The data presented at AACR contribute to the growing body of
evidence regarding the importance of telomerase targeted ...
Lpath Demonstrates 'First-in-Class' AMD Results With Its Lead Drug
... Lpathomab(TM), is a monoclonal
antibody against lysophosphatidic acid (LPA), a key bioactive lipid
that has been long recognized as a significant promoter
cancer-cell growth and metastasis in a broad range of tumor
Lpath's unique ability to generate antibodies against bioactive
lipids is ...